Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

In a large observational study in patients with COVID-19 and cancer, survival was not significantly influenced by receipt of COVID-19 treatments, except hydroxychloroquine plus any other treatment, which was associated with reduced survival.

[1]  S. Lofgren,et al.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2020, Annals of Internal Medicine.

[2]  Lee-Jen Wei,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[3]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[4]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[5]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[6]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[7]  R. Bhattacharyya,et al.  Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[8]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[9]  Amit N. Patel,et al.  Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[10]  Jun Yu Li,et al.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[11]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[12]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[13]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[14]  E. Price-Haywood,et al.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.

[15]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[16]  Amit N. Patel,et al.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[17]  J. Sterne,et al.  Collider bias undermines our understanding of COVID-19 disease risk and severity , 2020, Nature Communications.

[18]  R. Cumming,et al.  Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards , 2020, Journal of Epidemiology & Community Health.

[19]  Adolph Reed,et al.  Racial Health Disparities and Covid-19 - Caution and Context. , 2020, The New England journal of medicine.

[20]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[21]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[22]  J. Warner,et al.  The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer , 2020, Cancer Cell.

[23]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[24]  Jeremy Warner,et al.  Crowdsourcing a crisis response for COVID-19 in oncology , 2020, Nature Cancer.

[25]  C. Yancy,et al.  COVID-19 and African Americans. , 2020, JAMA.

[26]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[27]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[28]  M. Chua,et al.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[29]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[30]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[32]  Louise Bowman,et al.  The Magic of Randomization versus the Myth of Real-World Evidence. , 2020, The New England journal of medicine.

[33]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[34]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[35]  E. Paskett,et al.  Overcoming Barriers to Clinical Trial Enrollment. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[36]  N. Curtis,et al.  The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms , 2018, Front. Immunol..

[37]  Hanspeter Pfister,et al.  UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.

[38]  Søren Højsgaard,et al.  A Kenward-Roger approximation and parametric bootstrap methods for tests in linear mixed models: The R Package pbkrtest , 2014 .

[39]  Kosuke Imai,et al.  mediation: R Package for Causal Mediation Analysis , 2014 .

[40]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[41]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[42]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[43]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[44]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[45]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[46]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[47]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .